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Introduction Obstructive sleep apnoea (OSA) is
characterised by a loss of neuromuscular tone of the
upper airway dilator muscles while asleep. This study
investigated the effectiveness of transcutaneous electrical
stimulation in patients with OSA.
Patients and methods This was a randomised,
sham-controlled crossover trial using transcutaneous
electrical stimulation of the upper airway dilator muscles
in patients with conﬁrmed OSA. Patients were randomly
assigned to one night of sham stimulation and one night
of active treatment. The primary outcome was the 4%
oxygen desaturation index, responders were deﬁned as
patients with a reduction >25% in the oxygen
desaturation index when compared with sham
stimulation and/or with an index <5/hour in the active
treatment night.
Results In 36 patients (age mean 50.8 (SD 11.2)
years, male/female 30/6, body mass index median 29.6
(IQR 26.9–34.9) kg/m2, Epworth Sleepiness Scale 10.5
(4.6) points, oxygen desaturation index median 25.7
(16.0–49.1)/hour, apnoea-hypopnoea index median
28.1 (19.0–57.0)/hour) the primary outcome measure
improved when comparing sham stimulation (median
26.9 (17.5–39.5)/hour) with active treatment (median
19.5 (11.6–40.0)/hour; p=0.026), a modest reduction of
the mean by 4.1 (95% CI −0.6 to 8.9)/hour. Secondary
outcome parameters of patients’ perception indicated
that stimulation was well tolerated. Responders (47.2%)
were predominantly from the mild-to-moderate OSA
category. In this subgroup, the oxygen desaturation
index was reduced by 10.0 (95% CI 3.9 to 16.0)/hour
(p<0.001) and the apnoea-hypopnoea index was
reduced by 9.1 (95% CI 2.0 to 16.2)/hour (p=0.004).
Conclusion Transcutaneous electrical stimulation of the
pharyngeal dilators during a single night in patients with
OSA improves upper airway obstruction and is well
tolerated.
Trial registration number: NCT01661712.
INTRODUCTION
Obstructive sleep apnoea (OSA) is the most
common form of sleep-disordered breathing1 and
is widely recognised as a risk factor for cardiovas-
cular diseases.2 The prevalence of OSA continues
to rise, imposing a worldwide burden on public
health and currently affecting 10% of middle-aged
men and 3% of women aged 30–49 years in the
USA.3 The principle evidence-based treatment for
OSA, in addition to weight loss, is continuous posi-
tive airway pressure (CPAP);4 however, CPAP is fre-
quently not tolerated over longer periods, with a
quarter of patients being non-compliant within
weeks and half of all patients not using the equip-
ment after 1 year.5 Alternative therapies are needed
to reduce symptoms and health risks for patients
who fail CPAP treatment.
In 1978, Remmers et al6 described the patho-
physiology of upper airway obstruction in sleep
apnoea. Since then several research groups have
observed that electrical stimulation of the upper
airway could result in an increased tone of the
dilator muscles of the upper airway,7 thereby enab-
ling patients to maintain a patent upper airway
while asleep.8 9 In 2014, hypoglossal nerve stimula-
tion using an implantable stimulator was approved
by the US Food and Drug Administration for the
treatment of OSA following earlier publication of
the results of the STAR trial.10
Previously, Miki et al11 12 demonstrated that
transcutaneous electrical stimulation was effective
in reducing the apnoea index and duration and
improved oxygen saturation; however, other
researchers could not replicate these results.13 14
Key messages
What is the key question?
▸ Can electrical current be delivered
non-invasively via transcutaneous patches with
ongoing stimulation for the entire night?
What is the bottom line?
▸ The current trial provides evidence that
transcutaneous electrical stimulation of the
upper airway dilator muscles, a non-invasive
approach, delivered throughout the night
improves sleep apnoea.
Why read on?
▸ It is important to further reﬁne transcutaneous
electrical stimulation of the upper airway
dilator muscles, as this method offers a
promising and novel approach in the range of
non-CPAP therapies for patients with
obstructive sleep apnoea.
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In 2011, our group showed that continuous transcutaneous elec-
trical stimulation (CTES) was a feasible and effective approach
to stimulate the upper airway dilator muscles during short
periods while asleep.15
In this trial, the aim was to conduct a randomised, sham-
controlled and double-blind clinical trial to test the effectiveness
and safety of overnight transcutaneous electrical stimulation of
the upper airway muscles in patients with OSA.
PATIENTS AND METHODS
This sham-controlled and randomised crossover trial was
approved by the London ethics committee for clinical trials
(London-Dulwich, UK; 12/LO/1428) and was registered in
ClinicalTrials.gov (NCT01661712). We enrolled patients
referred to Guy’s and St Thomas’ and the Royal Brompton &
Hareﬁeld NHS Foundation Trusts sleep services (both London,
UK) for treatment of OSA between March 2013 and December
2015 when we achieved the full sample size. All patients were
provided with a patient information sheet and informed written
consent was obtained prior to enrolment (ﬁgure 1).16
Inclusion and exclusion criteria
The study included patients aged 18–75 years with a body mass
index (BMI) between 18 and 40 kg/m2 who had OSA with an
oxygen desaturation index (4%ODI) ≥15/hour or with an ODI
≥5/hour plus an Epworth Sleepiness Scale (ESS) >10 points.
Exclusion criteria were obesity-hypoventilation syndrome, sig-
niﬁcant airway obstruction, acute or critical illness.
Polysomnography
Patients underwent nocturnal full polysomnography (Alice5
equipment, Respironics, Murrysville, Pennsylvania, USA) at
baseline and during randomly allocated sham electrical stimula-
tion and active electrical stimulation nights. These three nights
were recorded with a gap of at least 3 days to provide
‘wash-out’ periods.
Interventional sleep studies
Patients were randomised in a crossover design into one of two
treatment arms; either they underwent polysomnography plus
CTES during the ﬁrst study night (‘active treatment’) followed
by another polysomnography plus sham-CTES during a second
night, at least three nights later (‘washout period’) or they
underwent the tests in the reverse order (ﬁgure 1).
Transcutaneous electrical stimulation
To deliver CTES, a speciﬁcally tailored electrical stimulator was
employed (SOSATS device, Morgan Innovation and Technology/
MIAT, Petersﬁeld, UK) which was connected to a laptop
(Toshiba, Tokyo/Japan) via a standard USB cable. A stimulation
lead from the device was attached bilaterally to the patient’s neck
via two 4×4 cm patches (Verity Medical, Hampshire, UK) placed
bilaterally halfway between the chin and the angle of the man-
dible over the submental area, as previously described (see online
supplementary material).15 Sham-CTES included the placement
of the stimulation patches and a stimulation marker that was dis-
played on the computer screen; no electrical current was applied.
Outcome measures
The primary outcome measure for this trial was the 4%ODI/hour
of sleep (events/hour). The 4%ODI was chosen as the primary
outcome parameter in preference to the apnoea-hypopnoea index
(AHI). Secondary outcome measures were AHI, nocturnal oxygen
saturation levels and nadir oxygenation and sleepiness, as
measured by the Stanford Sleepiness Scale. Patient comfort and
device acceptance were measured by administering ad-hoc visual
analogue scales on waking after sham and stimulation sleep studies
(see online supplementary material). Last, a post-hoc analysis was
performed to determine responders whose ODI had improved by
>25% compared with sham night and/or the total ODI was <5/
hour.
Sample size calculation
A sample size calculation for the primary outcome, 4%ODI,
was performed based on the results of a feasibility study.15
A sample size of 30 patients would achieve 90% power to
detect a mean of paired differences between the treatments of
17.9 events/hour with an estimated SD of differences of 18.9
events/hour and with a signiﬁcance level of 5% using a two-
sided Wilcoxon test assuming that the actual distribution was
normal. To adjust for the unknown distribution of the primary
outcome and based on the lower bound for the asymptotic rela-
tive efﬁciency of the Wilcoxon test, the required sample size was
increased by 20% to 36 patients. Further accounting for a
dropout and loss-to-follow-up rate of up to 20%, consistent
with the experience from previous studies of this type, a total
sample size of 44 patients was required for inclusion in the trial.
The effect size of the expected difference which the study was
powered for was aligned with the range of severity of sleep
apnoea: the threshold between mild and moderate OSA is an
AHI of 15 events/hour and the threshold between moderate and
severe sleep apnoea is an AHI of 30 events/hour. We wanted to
demonstrate that electrical stimulation was able to reduce OSA
severity by at least 15 events/hour allowing for a drop in severity
by one class (eg, the severe to the moderate range or from the
moderate to the mild range).
Statistical analysis
The differences in primary and secondary outcome measures
between the ‘active treatment’ and ‘sham intervention’ were
compared in a paired design (crossover trial) using SPSS
Statistics (V.23; IBM, New York, USA). To compare study
groups, the Wilcoxon (4%ODI) and paired t test for continuous
paired variables were used. To identify predictors of response a
stepwise multiple linear regression including the variables ‘age’,
‘gender’ and OSA severity (‘ODI’) was performed. The
McNemar’s χ2 test for nominal variables was used for the
gender comparison in the responder group. The 95% CI was
used to describe the treatment response. The level of signiﬁ-
cance was selected at p<0.05.
(For additional information on the methods and measure-
ments, please refer to the online supplementary material).
RESULTS
Patient characteristics
A total of 390 patients were assessed in order to determine the
eligibility for this trial. Following initial assessment, 44 patients
were further screened and underwent baseline polysomnogra-
phy (ﬁrst sleep study). Eight patients were excluded as screening
failures and 36 patients were randomised in a crossover design
and allocated to receive either active or sham treatment ﬁrst.
The participants returned for the ﬁrst treatment night (second
sleep study) after at least 3 days. After a ‘washout period’ of at
least another 3 days, participants returned for the opposite treat-
ment during the second treatment night (third sleep study). All
36 patients completed the trial after the third polysomnography
and were included in the analysis (ﬁgure 1).
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The studied patients were middle-aged, predominantly
Caucasian male subjects and overweight-to-obese. The neck
circumference was increased, the pharyngeal lumen was nar-
rowed—only eight patients had a Mallampati score of I—and
across the cohort there was a neutral waist-to-hip mass distri-
bution. Participants were sleepy, as assessed by the ESS and
had well-preserved lung function and normal daytime oxygen-
ation. The past medical history indicated limited use of
alcohol and nicotine (table 1). About 27.8% of patients had
hypertension, 19.4% dyslipidaemia and 8.3% had type II
diabetes.
Baseline polysomnography
Participants had predominantly moderate-to-severe OSA with
more severe upper airway obstruction in the supine posture, the
majority of respiratory events being obstructive apnoea. Sleep
was fragmented with an increased time of ‘wakefulness after
sleep onset’ and reduced sleep efﬁciency. Normal sleep architec-
ture was preserved, although rapid eye movement (REM) sleep
latency was delayed. Snoring was observed during more than
10% of the night (table 2).
Primary and physiological outcome parameters
During active treatment (current of 626.1 mA (409.8 mA)), the
primary outcome of the trial, the ODI, improved modestly, with
a mean of 4.1/hour (95% CI −0.6 to 8.9) for the whole group,
when comparing with sham stimulation (ﬁgures 2 and 3). No
differences were observed in the oxygenation levels and there
were no signiﬁcant improvements in the AHI or the supine
AHI. Polysomnographic data revealed a similar sleep architec-
ture and duration as observed at baseline with a reduction in N1
during the active treatment (table 3). The analysis of the
apnoea:hypopnoea ratio revealed that the ratio was 1.59 (0.75–
17.12) during the baseline sleep study and 0.82 (0.25–2.81)
during the stimulation night (p<0.001), indicating a higher
contribution of apnoea to the AHI without treatment.
Secondary outcome parameters
The patients’ device acceptance was good with patients report-
ing no skin discomfort or unpleasant sensations at night. There
was no difference in patients’ perceived sleep quality between
the sham stimulation and the active treatment, but patients
reported an improvement of their dry mouth after active
Figure 1 Consort diagram for the TESLA trial. AHI, apnoea-hypopnoea index; ODI, oxygen desaturation index.
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treatment (table 4). The only signiﬁcant side effect observed was
one patient who complained about claustrophobia at night; this
was during both treatment nights. The total count of mild side
effects occurred in 2.8% of the studied cohort and there were
no severe adverse events.
Responder group analysis
While the primary outcome parameter improved modestly for
the whole cohort, in 17 of 36 patients the ODI improved by
>25% compared with sham night and/or the total ODI
became <5/hour. This group had similar baseline character-
istics as the whole cohort, but subjects were more likely to
have mild-to-moderate OSA and to be of female gender
(table 5). In these ‘responders’, 4%ODI improved by 10.0/
hour (95% CI 3.9 to 16.0) (ﬁgure 4) and the AHI by 9.1/hour
(2.0–16.2) (ﬁgure 5).
In the total study cohort, there were 6 patients with mild
OSA, all of whom responded; 13 patients with moderate OSA,
with six responders (46.2%) and 17 patients with severe OSA,
of whom ﬁve were responders (29.4%). There was a low nega-
tive correlation between ODI and the response to stimulation
and the AHI and the response, respectively (r=−0.334,
p=0.023 and r=−0.320, p=0.029, respectively). A stepwise
multiple linear regression including the variables ‘age’, ‘gender’
and OSA severity (‘ODI’) at baseline identiﬁed only the ODI as
an independent predictor for response (standardised β=0.348;
95% CI 0.012 to 0.372). The regression model with ODI sever-
ity at baseline predicted about 10% of the response variance
(R2=0.121, adjusted R2=0.095, p=0.037). Age (p=0.851) and
gender (p=0.720) were excluded from the model (see online
supplementary material). There were no further signiﬁcant cor-
relations or predictors to identify responders.
A further subgroup analysis using more stringent criteria for
treatment response revealed that 7 of the 36 patients (19.4%)
had a reduction in the AHI of >50% when compared with
sham stimulation. Out of this group, 2 of the 36 patients
(5.6%) had a residual AHI <10/h during electrical stimulation
and a total of 6 of the 36 patients (16.7%) had an AHI <15/
hour, which would indicate mild OSA. In the responder group,
2 of the 17 patients (11.7%) had an ODI <5 events/hour
during sham treatment. When taking the data of these two
patients out the Wilcoxon signed-rank test, there was still a sig-
niﬁcant difference between the two groups (Z-value −3.4078,
p=0.00064).
DISCUSSION
This is the ﬁrst randomised, sham-controlled and double-blind
clinical trial testing the feasibility of transcutaneous electrical
stimulation of the pharyngeal dilator muscles in OSA for a
whole night. The primary outcome, improvement in the ODI,
revealed a modest improvement for the whole group compared
with sham stimulation. The majority of the participants
improved their sleep-disordered breathing and almost half of
the studied participants were identiﬁed as responders with an
improvement by a clinically relevant margin. Although the total
AHI did not change during stimulation, there was a shift in the
ratio of obstructive apnoea:hypopnoea when electrical current
Table 1 Demographic details of the patients included in the study (n=36)
Parameters Data Treatment first Sham first p Value
Age (years) 50.8 (11.2) 51.2 (11.9) 50.6 (11) 0.89
Sex (males/females) 30/6 13/1 17/5 0.22
White British, n (%) 29 (80.5) 12 (85.7) 17 (77.2) <0.05
Caribbean, n (%) 3 (8.3) 1 (7.1) 2 (9.1) 0.83
African, n (%) 2 (5.5) 1 (7.1) 1 (4.5) 0.74
Indian, n (%) 1 (2.7) 0 1 (4.5) 0.41
White other, n (%) 1 (2.7) 0 1 (4.5) 0.41
Height (cm) 175.3 (8.4) 175.6 (6.4) 175.1 (9.6) 0.83
Weight (kg) 95.8 (17.7) 93.8 (17.7) 97.1 (18.1) 0.59
BMI (kg/m2)* 29.7 (26.9–34.9) 28.4 (26.6–35) 30.6 (27.4–34.9) 0.44
Neck circumference (cm) 42.6 (3.8) 42.0 (2.9) 42.9 (4.2) 0.42
Waist circumference (cm) 103.8 (16.5) 104.4 (14.1) 103.4 (18.2) 0.85
Hip circumference (cm)* 105.0 (99.0–111.0) 107.2 (99.8–111.0) 104.5 (98.3–108.0) 0.26
Waist:hip ratio 0.99 (0.08) 0.98 (0.07) 1.00 (0.08) 0.29
Mallampati score I, n (%) 8 (22.2) 4 (28.5) 4 (18.1) 0.56
Mallampati score II, n (%) 15 (41.6) 4 (28.5) 11 (50) 0.2
Mallampati score III, n (%) 8 (22.2) 5 (35.7) 3 (13.6) 0.12
Mallampati score IV, n (%) 5 (13.8) 1 (7.1) 4 (18.1) 0.35
ESS (points) 10.5 (4.6) 11.4 (4.6) 10 (4.5) 0.39
FEV1 (L) 3.13 (0.82) 2.94 (0.73) 3.25 (0.86) 0.26
FVC (L) 4.08 (0.89) 3.89 (0.86) 4.20 (1.07) 0.34
FEV1/FVC (%) 76.8 (8.2) 75.7 (9.9) 77.4 (7.0) 0.58
SpO2 awake (%) 94.6 (1.0) 94.7 (0.6) 94.5 (1.2) 0.43
Previous treatment: none/CPAP, n (%) 18 (50.0)/18 (50.0) 7 (50.0)/7 (50.0) 11 (50.0)/11 (50.0) 1.0
Alcohol consumption (units/week)* 2.0 (0.0–10.5) 1 (0.0–5.9) 4 (0–11.5) 0.49
Pack-years (years)* (12 lifelong non-smokers, 24 current or ex-smokers) 10.0 (5.0–14.3) 10.0 (6.5–12.1) 10.0 (5–15) 0.55
*Data were non-normally distributed and are expressed as median and IQR. Pack-years are calculated for current and ex-smokers only (n=24).
BMI, body mass index; ESS, Epworth Sleepiness Scale; SpO2: oxygen saturation.
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was applied. This observation indicates a resolution of the
upper airway obstruction during apnoeas with electrical
stimulation.
Secondary outcome parameters were related to patients’ per-
ception of stimulation and sleepiness, snoring, oxygen saturations
and side effects. Patients’ sleep quality, polysomnographically
determined sleep architecture and sleep duration were not
adversely affected by the use of electrical stimulation. There were
no signiﬁcant adverse events during the trial and patients did not
experience any pain or skin discomfort. Claustrophobia was
observed during two nights in a single patient (sham and true
stimulation night). Snoring, average and nadir oxygen saturations
were not altered by stimulation in this cohort; however, partici-
pants experienced fewer problems with a dry mouth following
the night with electrical stimulation.
Table 2 Baseline polysomnography data of the studied patients
(n=36)
Parameters Results
ODI (events/hour)* 25.7 (16.0–49.1)
AHI (events/hour)* 28.1 (19.0–57.0)
Obstructive apnoea (events/hour)* 15.2 (6.7–31.4)
Central apnoea (events/hour)* 0.1 (0.0–0.5)
Mixed apnoea (events/hour)* 0.2 (0.0–1.9)
Obstructive hypopnoea (events/hour)* 7.8 (1.2–14.3)
Supine AHI (events/hour) 43.2 (27.0)
REM AHI (events/hour) 36.7 (24.9)
Arousal index (events/hour) 28.7 (14.8)
SpO2 asleep (%) 93.3 (1.6)
Nadir SpO2 asleep (%)* 80.5 (74.0–85.0)
Total sleep time (min) 337.5 (75.3)
Time in bed (min) 448.4 (51.8)
Sleep efficiency (%) 74.9 (15.1)
Sleep onset (min)* 18.8 (9.0–39.1)
Wake after sleep onset (min)* 79.0 (35.9–117.2)
REM latency (min)* 131.0 (69.5–162.5)
Sleep stage N1 (%)* 13.0 (8.3–18.7)
Sleep stage N2 (%) 50.7 (15.1)
Sleep stage N3 (%) 16.3 (12.8)
Sleep stage REM (%) 15.7 (9.3)
Snoring time (min)* 43.3 (15.2–72.4)
Snoring time (%)* 13.2 (5.5–22.3)
*Data were non-normally distributed and are expressed as median and IQR.
Sleep stages and snoring time are expressed as percentage of time asleep.
AHI, apnoea-hypopnoea index; N1–N3, non-REM sleep stages 1–3; ODI, 4% oxygen
desaturation index; REM, rapid eye movement; SpO2, oxygen saturation.
Figure 2 Box-and-whisker plot for the 4% oxygen desaturation index
(4%ODI) in all studied patients (n=36).
Figure 3 Box-and-whisker plot for the apnoea-hypopnoea index (AHI)
in all studied patients (n=36).
Table 3 Respiratory and polysomnography data during sham
treatment night compared with active treatment
Parameters Sham stimulation Active treatment p Value
ODI (events/hour)* 26.9 (17.5–39.5) 19.5 (11.6–40.0) 0.026
AHI (events/hour)* 33.8 (16.6–46.1) 23.7 (11.4–47.6) 0.20
Obstructive apnoea
(events/hour)*
9.9 (3.8–32.4) 7.6 (3.4–30.0) 0.21
Central apnoea
(events/hour)*
0.5 (0.0–1.8) 0.4 (0.0–0.9) 0.53
Mixed apnoea (events/
hour)*
0.5 (0.0–2.1) 0.1 (0.0–1.7) 0.68
Obstructive hypopnoea
(events/hour)*
12.7 (3.0–23.6) 7.8 (4.5–15.6) 0.42
Supine AHI
(events/hour)
44.9 (24.2) 38.6 (25.9) 0.09
REM AHI (events/hour) 35.2 (26.0) 31.3 (23.9) 0.50
Arousal index
(events/hour)
28.8 (16.9) 22.6 (16.9) 0.007
SpO2 asleep (%) 93.2 (2.0) 93.2 (2.2) 0.48
Nadir SpO2
asleep (%)*
80.5 (74.5–86.0) 81.0 (74.0–84.0) 0.58
Total sleep time (min)* 366.3 (323.6–409.0) 356.8 (340.8–396.4) 0.41
Time in bed (min)* 452.0 (424.4–475.0) 447.3 (406.6–483.2) 0.77
Sleep efficiency (%)* 83.8 (70.9–89.3) 84.2 (69.1–89.0) 0.60
Sleep onset (min)* 14.5 (5.6–39.8) 17.0 (3.9–47.9) 0.17
Wake after sleep
onset (min)*
51.5 (29.4–97.3) 52.3 (29.4–89.8) 0.52
REM latency (min)* 94.0 (64.1–156.6) 89.0 (64.0–132.0) 0.85
Sleep stage N1 (%)* 10.2 (7.0–20.3) 9.8 (6.3–15.0) 0.039
Sleep stage N2 (%)* 49.9 (40.0–58.8) 51.4 (43.1–65.6) 0.32
Sleep stage N3 (%) 15.7 (11.6) 15.4 (10.0) 0.76
Sleep stage REM (%) 16.9 (9.2) 16.0 (8.4) 0.50
Snoring time (min)* 64.6 (23.0–140.8) 46.3 (26.0–125.4) 0.45
Snoring time (%)* 19.9 (6.1–35.9) 17.0 (7.6–28.7) 0.47
*Data were non-normally distributed and are expressed as median and IQR.
AHI, apnoea-hypopnoea index; N1–N3, sleep stages; ODI, 4% oxygen desaturation
index; REM, rapid eye movement sleep; SpO2, oxygen saturation.
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Clinical relevance of transcutaneous stimulation
Electrical stimulation has long been studied as a technique to
inﬂuence upper airway dilator function in sleep. Prior studies
have reported both positive11 12 17 and negative13 14 results,
likely to reﬂect the heterogeneous populations studied and
different approaches used.7 An important point when using
this technique is to avoid arousals from sleep. For many
years, no further reports were published using the transcuta-
neous technique. Following on from our own feasibility
study,15 the current trial used a titration algorithm during
wakefulness to deﬁne individual skin sensation thresholds of
electrical current to enable unproblematic nocturnal use of
currents within the range observed to be comfortable while
awake.
CTES rather than intermittent or inspiratory-triggered stimu-
lation bursts is less likely to trigger uncomfortable skin sensa-
tion, as changes in current intensity activate speciﬁc skin
receptors; CTES has the advantage of working with a single-
channel device (‘pacing’) without the need for ‘sensing’. The use
of continuous low current requires less force to maintain the
neuromuscular tone in the upper airway than intermittent
stimulation as it is easier to maintain upper airway patency than
to initiate the reopening of an occluded airway. It is important
that this approach can be used for prolonged periods in patients
with sleep apnoea with no apparent adverse effect on sleep
quality or sleep duration.
Hypoglossal neural stimulation
Several recent studies have investigated the use of an implanta-
ble electrical stimulator to target the distal branch of the hypo-
glossal nerve that innervates the genioglossus.8–10 18 19 The
Clinical Trial by Apnex Medical (Roseville, Minnesota, USA;
NCT01446601) was terminated prematurely because the
primary outcome, a reduction in OSA severity (deﬁned as AHI
reduction >50% and AHI <20 and ODI 4% reduction ≥25%
or ODI 4% <5 from baseline to 6-month follow-up) was not
met. In contrast, the STAR trial achieved positive results.10 An
important feature of the STAR trial was sophisticated screening
to identify potential ‘responders’ to the treatment. The investi-
gators excluded patients with pronounced anatomical abnormal-
ities of the upper airway and those with concentric collapse of
the retropalatal airway, as assessed by endoscopy during
drug-induced sleep.10 After screening 929 patients, 126 partici-
pants had a device implanted and 124 completed the trial.
Table 4 Assessment of symptoms and side effects when waking
after the sham stimulation and active treatment nights, as
measured by a visual analogue scale (0–10 points)—higher scores
indicate an improvement
Parameters Sham stimulation Active treatment p Value
Feeling refreshed 5.7 (2.7–7.2) 6.6 (2.2–8.5) 0.40
Sleep quality 5.6 (2.9–7.1) 6.4 (2.4–8.0) 0.28
Mouth dryness 4.4 (2.2–8.5) 7.4 (4.9–9.7) 0.007
Tongue unpleasant
sensation
9.9 (9.4–10.0) 9.9 (9.4–10.0) 0.63
Morning headache 9.4 (6.3–10.0) 9.9 (8.1–10.0) 0.27
Skin discomfort 9.9 (9.5–10.0) 9.9 (9.7–10.0) 0.95
Sleepiness* 3.0 (2.0–3.5) 3.0 (2.0–3.0) 0.29
*Sleepiness was assessed in the mornings using the Stanford Sleepiness Scale to pick
up ad-hoc changes. All variables are presented as median and IQR.






Age (years) 48.4 (11.4) 53.0 (10.8) 0.22
Sex (males/females) 13/4 17/2 0.007
BMI (kg/m2) 32.3 (5.4) 30.0 (3.0) 0.19
Neck size (cm) 42.6 (2.8) 42.5 (4.5) 0.97
Mallampati score I, n (%) 3 (17.6) 5 (26.3) 0.53
Mallampati score II, n (%) 5 (29.4) 10 (52.6) 0.26
Mallampati score III, n (%) 6 (35.2) 2 (10.5) 0.07
Mallampati score IV, n (%) 3 (17.6) 4 (21.0) 0.63
Waist:hip ratio 0.98 (0.06) 0.99 (0.08) 0.67
ESS (points)* 10.0 (8.0–13.0) 13.0 (7.5–15.0) 0.14
*Data expressed as median and IQR.
BMI, body mass index; ESS, Epworth Sleepiness Scale; n, number.
Figure 4 Box-and-whisker plot for the 4% oxygen desaturation index
(4%ODI) among ‘responders’ (n=17). There is a signiﬁcant
improvement in the primary outcome between sham stimulation night
and active treatment night.
Figure 5 Box-and-whisker plot for the apnoea-hypopnoea index (AHI)
among ‘responders’ (n=17). There is a signiﬁcant improvement in the
primary outcome between sham stimulation night and active treatment
night.
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At 12 months the median AHI was reduced by 68% from 29.3/
hour to 9.0/hour. In a randomised therapy-withdrawal arm the
features of sleep apnoea were again observed when the treat-
ment was discontinued (AHI 25.8/hour; ODI 23.0/hour). In the
STAR trial, 56 patients were excluded from implantation follow-
ing endoscopy during drug-induced sleep and 13 patients were
excluded because of anatomical abnormalities of the upper
airway following surgical consultation.
Compared with hypoglossal nerve stimulation, the effect size
of CTES in the current trial is smaller. Several factors can
explain this observation: the delivery of effective electrical
current to the muscles is affected by skin and soft tissue resist-
ance; in patients with large neck circumference, this can be a
signiﬁcant limitation. Stimulation frequency, duration and wave-
form need to be considered when stimulating for longer periods
to maintain force generation while avoiding muscle fatigue.
Last, the intensity of the electrical current is dependent on indi-
vidual comfort and perception and titration of the current needs
to be tailored to patient’s individual perception of skin discom-
fort to avoid arousal from sleep. Future studies using transcuta-
neous electrical stimulation will need to consider the level of
obstruction of the upper airway to identify potential responders
prior to enrolment in trials. Transcutaneous electrical stimula-
tion might also be used to test patients prior to implanting
hypoglossal nerve stimulators to test the individual response.
Responders to transcutaneous electrical stimulation
In the current trial, 17 of the 36 participants (47.2%) had
improvement in OSA severity during the electrical stimulation
night, as deﬁned by the ODI and the AHI.10 From the studied
cohort, it appears that this method is more suitable for milder
disease and in female subjects. In the multivariate analysis none
of the studied characteristics or demographics seemed to be
associated with responsiveness. The neck anatomy and the dis-
tance between dilator muscles and dermal patches as well as the
threshold of comfort for the effective current are likely to be
further determinants of effectiveness.
Effect on REM sleep AHI
In REM sleep, the peripheral skeletal muscles are in a state of
physiological atonia during which the work of breathing is pre-
dominantly delivered by the diaphragm. The tone of the upper
airway dilator muscles is reduced and the critical occlusion pres-
sure can signiﬁcantly increase making it more likely that the sub-
jects experience obstruction and collapse of the upper airway as
the positive intramural and the negative inspiratory pressure gra-
dients favour unopposed occlusion.
It is therefore of interest to understand how transcutaneous
electrical stimulation impacts on the stability of the upper airway,
as indicated by the AHI. For the whole group, the REM-sleep
related AHI did not signiﬁcantly improve (REM AHI for sham
stimulation 35.3 (26.0) versus active treatment 31.3 (23.9)/hour,
p=0.50) and this might indicate that the force to maintain upper
airway patency is not strong enough in REM sleep due to the
increased load and reduced endogenous neuromuscular tone.
However, neither ‘responders’ nor ‘non-responders’ improved
their REM AHI signiﬁcantly with stimulation (p=0.282 for
responders, p=0.725 for non-responders), but responders had a
lower REM AHI than non-responders with active stimulation
(non-responders REM AHI 36.9 (13.3–56.8) versus responders
REM AHI 13.3 (6.7–32.7)/hour, p=0.044). This is consistent
with the observation that patients with milder forms of sleep
apnoea who were less obese were more likely to be responders.
Subjective perception of transcutaneous electrical stimulation
Previous studies using transcutaneous electrical stimulation for
the treatment of sleep apnoea did not apply electrical current
for the whole night. The TESLA data on patients’ perception
importantly highlight the feasibility of the method, with patients
remaining asleep with no difference in their sleep proﬁle com-
pared with sham stimulation. Sleep quality was not adversely
affected. Following the sham stimulation, patients complained
more about a dry mouth in the morning than after active treat-
ment. Whether this is a feature of a more patent upper airway at
night or the mouth being closed remains to be elucidated.
Snoring in patients with sleep apnoea
The current trial failed to reduce snoring duration during stimu-
lation nights in patients with sleep apnoea. The breakdown of
the AHI shifted during electrical stimulation, the obstructive
apnoea:hypopnoea ratio during the baseline sleep study was
1.59 vs 0.82 during active treatment. This indicates a preferen-
tial resolution of apnoea with electrical stimulation. However,
continued ﬂow-limited breathing during ongoing hypopnoea is
likely to contribute to the total time of snoring. In comparison,
there was absence of airﬂow during obstructive apnoea and no
snoring sound. Whether snoring in patients with milder sleep
apnoea, patients with upper airway resistance syndrome or
snorers without ﬂow limitation would improve using this treat-
ment remains to be studied.
Stimulation pattern
The way electrical current can be used to stimulate the upper
airway dilator muscles transcutaneously is inﬂuenced by multiple
factors. Waveform (rectangle, triangular, single impulse,
rounded), polarity (unipolar, bipolar), frequency, intensity and
duration (continuous, intermittent, triggered) are important
factors to generate efﬁcient force and avoid muscle fatigue.
Following on from previous work, the current trial used bipolar
current, individually titrated by daytime in awake patients to
deﬁne the lower and upper current thresholds of skin sensation
at a frequency of 30 Hz.15 Inspiratory-triggered stimulation has
the advantage of avoiding fatigue but requires additional record-
ing for sensing of a physiological signal to identify inspiration
(eg, ﬂow, sound, inspiratory effort measuring either movement
or electromyography activity), live analysis and sophisticated
algorithms to stimulate the muscle at the right time. In contrast,
continuous stimulation, as previously used, is effective in avoid-
ing these problems; similar to CPAP therapy, the treatment is
provided all night but it is likely to cause muscle fatigue. The
stimulation pattern used for the TESLA trial (5 s on/5 s off ) was
chosen following initial studies to address these points; it does
not require additional sensing and its duty cycle will guarantee
stimulation during any potentially occurring apnoea which is
deﬁned as absence of airﬂow for >10 s. This pattern also pro-
vides sufﬁcient rest time for the muscle to avoid fatigue.
Limitations
Upper airway endoscopy during drug-induced sedation is pres-
ently not standard practice in the UK, but this technique might
be of theoretical value in selecting patients for this therapy by
describing the level of upper airway obstruction. Endoscopy was
not considered when screening patients for the current trial and
a better characterisation of the upper airway would likely have
led to a greater number of ‘non-responders’ being prospectively
excluded. Future trials using transcutaneous electrical stimula-
tion could screen for likely ‘responders’, deﬁne patient
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phenotypes, test the feasibility and effectiveness of this method
in the community and test whether it is sufﬁcient to treat
REM-related events. Endoscopy could also describe the site of
upper airway collapse during delivery of transcutaneous elec-
trical current. It is important to identify the impact of posture
in this method and whether a treatment effect is observed in the
non-supine posture. Determinants of effectiveness like posture
and neck ﬂexion should be studied in future. These points are
important in the context that 2 of the 17 responders had a
normal ODI in the sham night. Whether this improvement com-
pared with the baseline sleep study is due to the taping of the
submental region is unclear, but changes in the neuromuscular
tone due to increased afferent feedback could, in part, contrib-
ute to our ﬁndings. This study was set up to test transcutaneous
electrical stimulation for a single night only and it remains to be
shown whether use of dermal patches and transcutaneous stimu-
lation over longer follow-up periods is a feasible method and
whether responders beneﬁt symptomatically.
The double-blind study design of the TESLA trial was chosen
to minimise bias caused by patients’ or research staff perception
of the method. A computer mode provided random selection of
active treatment or sham stimulation. Once the mode was
selected, the computer indicated at night that stimulation was
delivered, independent of whether it was sham stimulation or
active treatment, to simulate a potential stimulation artefact.
Independent experienced technicians from the sleep laboratory
were assigned for the ofﬂine analysis after the patients had been
studied over all three nights. The data were then inserted in the
database by a different investigator, still in the randomised order
and without access to the respective raw data of the polysomno-
graphy. After the last patient had been studied and data acquisi-
tion had concluded, the data were unblinded in that the sham
stimulation nights’ data were separated from the active treat-
ment nights’ for analysis by the medical statistician. Any poten-
tially small stimulation artefact picked up in the technicians’
analysis of the original polysomnographies would not have been
reported to the trial’s team or the patient and is therefore
unlikely to have impacted on the trial’s outcome.
Only about 1 in 10 screened patients underwent randomisa-
tion and, therefore, the sample of the randomised patients does
not fully represent the whole cohort of patients with OSA.
However, it is not uncommon that strict adherence to a proto-
col requires screening of a large number of patients who, even-
tually, turn out to be excluded. In the STAR trial, Strollo et al10
conducted a randomised controlled trial of invasive electrical
stimulation in patients with OSA and they recruited 929 sub-
jects, of whom only 126 were randomised and included in the
treatment group (13.6%). Broader inclusion criteria could help
the generalisability of observed effects. However, particularly in
studies testing a novel therapeutic approach, the inclusion of
inappropriate patients could dilute the effect size, as it is likely
that these patients are less responsive. It should be pointed out
that this approach will not replace CPAP as the standard ﬁrst
choice therapy for OSA, but might beneﬁt some patients who
are unable to wear CPAP masks. Importantly, even patients who
are well established on standard treatment and compliant with
CPAP may wish to try novel and non-invasive alternatives.20
The prevalence of OSA is rising and even a modest response
using electrical stimulation could be helpful in avoiding symp-
toms and long-term risks in some of the patients who fail CPAP
therapy. However, it is important to note that the present study
was not powered to identify predictors of response and, there-
fore, the post-hoc results of the subgroup analysis must be inter-
preted with caution.
CONCLUSION
Transcutaneous electrical stimulation of the upper airway dilator
muscles in OSA can be safely delivered throughout the whole
night. Although we observed only a modest improvement in the
whole study cohort, approximately half of the studied population
were ‘responders’—predominantly those with mild-to-moderate
disease. Future use of this method should focus on the prospect-
ive identiﬁcation of responders. Deﬁning upper airway features of
those who could beneﬁt and assessing long-term symptomatic
improvements and feasibility of the method in the domiciliary
setting will be important to further develop this approach.
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